Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention

William W. Chu, Seung-Woon Rha, Pramod K. Kuchulakanti, Edouard Cheneau, Rebecca Torguson, Ellen Pinnow, Jana Alexieva-Fournadjiev, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Ron Waksman

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Saphenous vein graft (SVG) intervention is associated with a significantly increased rate of periprocedural complications and late clinical and angiographic restenosis. We examined the efficacy and safety of sirolimus-eluting stents (SESs; Cypher) compared with bare metal stents (BMSs) in SVG intervention. Forty-eight patients who had 50 SVG lesions and underwent standard percutaneous coronary intervention with SESs (SES group) were compared with 57 patients who had 64 SVG lesions and underwent intervention with BMSs (BMS group). All patients received distal protection devices during SVG intervention. In-hospital, 30-day, 6-month, and 1-year clinical outcomes in the 2 groups were compared. Baseline clinical and procedural characteristics were balanced between groups. There were no deaths or Q-wave myocardial infarctions during the index hospitalization, but compared with the BMS group, patients in the SES group had significantly fewer non-Q-wave myocardial infarctions (4% vs 21%, p = 0.01), which was mainly attributed to increased periprocedural creatine kinase-MB levels. At 30-day, 6-month, and 1-year follow-ups, all clinical outcomes were similar between groups. Event-free survival at 1 year was also similar between groups (p = 0.84). In conclusion, the use of SESs in patients who undergo SVG intervention with a distal protection device is clinically safe and feasible but is not associated with decreased clinical events up to 1 year compared with BMSs.

Original languageEnglish
Pages (from-to)34-37
Number of pages4
JournalAmerican Journal of Cardiology
Volume97
Issue number1
DOIs
Publication statusPublished - 2006 Jan 1
Externally publishedYes

Fingerprint

Saphenous Vein
Sirolimus
Stents
Metals
Transplants
Myocardial Infarction
MB Form Creatine Kinase
Equipment and Supplies
Percutaneous Coronary Intervention
Disease-Free Survival
Hospitalization
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. / Chu, William W.; Rha, Seung-Woon; Kuchulakanti, Pramod K.; Cheneau, Edouard; Torguson, Rebecca; Pinnow, Ellen; Alexieva-Fournadjiev, Jana; Pichard, Augusto D.; Satler, Lowell F.; Kent, Kenneth M.; Lindsay, Joseph; Waksman, Ron.

In: American Journal of Cardiology, Vol. 97, No. 1, 01.01.2006, p. 34-37.

Research output: Contribution to journalArticle

Chu, WW, Rha, S-W, Kuchulakanti, PK, Cheneau, E, Torguson, R, Pinnow, E, Alexieva-Fournadjiev, J, Pichard, AD, Satler, LF, Kent, KM, Lindsay, J & Waksman, R 2006, 'Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention', American Journal of Cardiology, vol. 97, no. 1, pp. 34-37. https://doi.org/10.1016/j.amjcard.2005.08.018
Chu, William W. ; Rha, Seung-Woon ; Kuchulakanti, Pramod K. ; Cheneau, Edouard ; Torguson, Rebecca ; Pinnow, Ellen ; Alexieva-Fournadjiev, Jana ; Pichard, Augusto D. ; Satler, Lowell F. ; Kent, Kenneth M. ; Lindsay, Joseph ; Waksman, Ron. / Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. In: American Journal of Cardiology. 2006 ; Vol. 97, No. 1. pp. 34-37.
@article{e7a7ba563afb47c3b992c17fb5735023,
title = "Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention",
abstract = "Saphenous vein graft (SVG) intervention is associated with a significantly increased rate of periprocedural complications and late clinical and angiographic restenosis. We examined the efficacy and safety of sirolimus-eluting stents (SESs; Cypher) compared with bare metal stents (BMSs) in SVG intervention. Forty-eight patients who had 50 SVG lesions and underwent standard percutaneous coronary intervention with SESs (SES group) were compared with 57 patients who had 64 SVG lesions and underwent intervention with BMSs (BMS group). All patients received distal protection devices during SVG intervention. In-hospital, 30-day, 6-month, and 1-year clinical outcomes in the 2 groups were compared. Baseline clinical and procedural characteristics were balanced between groups. There were no deaths or Q-wave myocardial infarctions during the index hospitalization, but compared with the BMS group, patients in the SES group had significantly fewer non-Q-wave myocardial infarctions (4{\%} vs 21{\%}, p = 0.01), which was mainly attributed to increased periprocedural creatine kinase-MB levels. At 30-day, 6-month, and 1-year follow-ups, all clinical outcomes were similar between groups. Event-free survival at 1 year was also similar between groups (p = 0.84). In conclusion, the use of SESs in patients who undergo SVG intervention with a distal protection device is clinically safe and feasible but is not associated with decreased clinical events up to 1 year compared with BMSs.",
author = "Chu, {William W.} and Seung-Woon Rha and Kuchulakanti, {Pramod K.} and Edouard Cheneau and Rebecca Torguson and Ellen Pinnow and Jana Alexieva-Fournadjiev and Pichard, {Augusto D.} and Satler, {Lowell F.} and Kent, {Kenneth M.} and Joseph Lindsay and Ron Waksman",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2005.08.018",
language = "English",
volume = "97",
pages = "34--37",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention

AU - Chu, William W.

AU - Rha, Seung-Woon

AU - Kuchulakanti, Pramod K.

AU - Cheneau, Edouard

AU - Torguson, Rebecca

AU - Pinnow, Ellen

AU - Alexieva-Fournadjiev, Jana

AU - Pichard, Augusto D.

AU - Satler, Lowell F.

AU - Kent, Kenneth M.

AU - Lindsay, Joseph

AU - Waksman, Ron

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Saphenous vein graft (SVG) intervention is associated with a significantly increased rate of periprocedural complications and late clinical and angiographic restenosis. We examined the efficacy and safety of sirolimus-eluting stents (SESs; Cypher) compared with bare metal stents (BMSs) in SVG intervention. Forty-eight patients who had 50 SVG lesions and underwent standard percutaneous coronary intervention with SESs (SES group) were compared with 57 patients who had 64 SVG lesions and underwent intervention with BMSs (BMS group). All patients received distal protection devices during SVG intervention. In-hospital, 30-day, 6-month, and 1-year clinical outcomes in the 2 groups were compared. Baseline clinical and procedural characteristics were balanced between groups. There were no deaths or Q-wave myocardial infarctions during the index hospitalization, but compared with the BMS group, patients in the SES group had significantly fewer non-Q-wave myocardial infarctions (4% vs 21%, p = 0.01), which was mainly attributed to increased periprocedural creatine kinase-MB levels. At 30-day, 6-month, and 1-year follow-ups, all clinical outcomes were similar between groups. Event-free survival at 1 year was also similar between groups (p = 0.84). In conclusion, the use of SESs in patients who undergo SVG intervention with a distal protection device is clinically safe and feasible but is not associated with decreased clinical events up to 1 year compared with BMSs.

AB - Saphenous vein graft (SVG) intervention is associated with a significantly increased rate of periprocedural complications and late clinical and angiographic restenosis. We examined the efficacy and safety of sirolimus-eluting stents (SESs; Cypher) compared with bare metal stents (BMSs) in SVG intervention. Forty-eight patients who had 50 SVG lesions and underwent standard percutaneous coronary intervention with SESs (SES group) were compared with 57 patients who had 64 SVG lesions and underwent intervention with BMSs (BMS group). All patients received distal protection devices during SVG intervention. In-hospital, 30-day, 6-month, and 1-year clinical outcomes in the 2 groups were compared. Baseline clinical and procedural characteristics were balanced between groups. There were no deaths or Q-wave myocardial infarctions during the index hospitalization, but compared with the BMS group, patients in the SES group had significantly fewer non-Q-wave myocardial infarctions (4% vs 21%, p = 0.01), which was mainly attributed to increased periprocedural creatine kinase-MB levels. At 30-day, 6-month, and 1-year follow-ups, all clinical outcomes were similar between groups. Event-free survival at 1 year was also similar between groups (p = 0.84). In conclusion, the use of SESs in patients who undergo SVG intervention with a distal protection device is clinically safe and feasible but is not associated with decreased clinical events up to 1 year compared with BMSs.

UR - http://www.scopus.com/inward/record.url?scp=29244439559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244439559&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.08.018

DO - 10.1016/j.amjcard.2005.08.018

M3 - Article

VL - 97

SP - 34

EP - 37

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -